1.
Massimiliano Bonifacio, Gianni Binotto, Elena Maino, Elisabetta Calistri, Luciana Marin, Luigi Scaffidi, Luca Frison, Federico De Marchi, Mauro Krampera, Giampiero Semenzato, Renato Fanin, Achille Ambrosetti, Mario Tiribelli. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica 2015;100(8):e299-e301; https://doi.org/10.3324/haematol.2015.124685.